Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

Introduction: The optimal management of large cell neuroendocrine cancer of the lung (LCNEC) is unclear, and data regarding anti–programmed cell death protein 1 (PD-1) antibodies are scarce. This study reports the clinical efficacy of a PD-1 inhibitor in patients with advanced LCNEC. Methods: All pa...

Full description

Bibliographic Details
Main Authors: Camille Agar, MD, Margaux Geier, MD, Guillaume Léveiller, MD, Régine Lamy, MD, Jean-Louis Bizec, MD, Marie Tiercin, MD, Cyril Bernier, MD, Gilles Robinet, MD, Hervé Léna, MD, Charles Ricordel, MD, Romain Corre, MD
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:JTO Clinical and Research Reports
Subjects:
Large-cell neuroendocrine cancer
Lung cancer
Immune checkpoint inhibitors
Nivolumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301806

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301806

Similar Items